Literature DB >> 20622048

Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.

Dennis J Goussetis1, Leonidas C Platanias.   

Abstract

Simultaneous targeting of the phosphoinositide 3-kinase (PI3K)/Akt pathway increases arsenic trioxide (ATO)-dependent cytotoxicity of chronic lymphocytic leukemia (CLL) cells, whereas it has no significant effects on normal lymphocytes. Combinations of ATO with small molecules that target PI3K and/or Akt may provide a novel approach for the treatment of CLL.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20622048      PMCID： PMC2932783          DOI： 10.1158/1078-0432.CCR-10-1496

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.

Authors:  Javier Redondo-Muñoz; Elizabeth Escobar-Díaz; Mercedes Hernández Del Cerro; Atanasio Pandiella; María José Terol; José A García-Marco; Angeles García-Pardo
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

2.  Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.

Authors:  Nick Giafis; Efstratios Katsoulidis; Antonella Sassano; Martin S Tallman; Linda S Higgins; Angel R Nebreda; Roger J Davis; Leonidas C Platanias
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

3.  Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.

Authors:  Patrick Yoon; Nick Giafis; Jessica Smith; Heather Mears; Efstratios Katsoulidis; Antonella Sassano; Jessica Altman; Amanda J Redig; Martin S Tallman; Leonidas C Platanias
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

Review 4.  Mechanisms of action of arsenic trioxide.

Authors:  Wilson H Miller; Hyman M Schipper; Janet S Lee; Jack Singer; Samuel Waxman
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

Review 5.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

6.  A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

Authors:  Thomas Decker; Michael Sandherr; Katharina Goetze; Madlen Oelsner; Ingo Ringshausen; Christian Peschel
Journal:  Ann Hematol       Date:  2008-08-14       Impact factor: 3.673

7.  JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells.

Authors:  Kelly Davison; Koren K Mann; Samuel Waxman; Wilson H Miller
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

Review 8.  Biological responses to arsenic compounds.

Authors:  Leonidas C Platanias
Journal:  J Biol Chem       Date:  2009-04-10       Impact factor: 5.157

9.  Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.

Authors:  Jessica K Altman; Patrick Yoon; Efstratios Katsoulidis; Barbara Kroczynska; Antonella Sassano; Amanda J Redig; Heather Glaser; Alison Jordan; Martin S Tallman; Nissim Hay; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2007-11-29       Impact factor: 5.157

10.  MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis.

Authors:  Paolo Lunghi; Antonio Costanzo; Luigi Salvatore; Nelida Noguera; Laura Mazzera; Antonio Tabilio; Francesco Lo-Coco; Massimo Levrero; Antonio Bonati
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113
View more
  10 in total

1.  Arsenic inhibits mast cell degranulation via suppression of early tyrosine phosphorylation events.

Authors:  Juyoung Shim; Rachel H Kennedy; Lisa M Weatherly; Lee M Hutchinson; Jonathan H Pelletier; Hina N Hashmi; Kayla Blais; Alejandro Velez; Julie A Gosse
Journal:  J Appl Toxicol       Date:  2016-03-28       Impact factor: 3.446

2.  Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.

Authors:  Jonathan B Bell; Frank Eckerdt; Harshil D Dhruv; Darren Finlay; Sen Peng; Seungchan Kim; Barbara Kroczynska; Elspeth M Beauchamp; Kristen Alley; Jessica Clymer; Stewart Goldman; Shi-Yuan Cheng; C David James; Ichiro Nakano; Craig Horbinski; Andrew P Mazar; Kristiina Vuori; Priya Kumthekar; Jeffrey Raizer; Michael E Berens; Leonidas C Platanias
Journal:  Mol Cancer Res       Date:  2017-10-17       Impact factor: 5.852

3.  Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin.

Authors:  Hui-Wen Chiu; Yuan-Soon Ho; Ying-Jan Wang
Journal:  J Mol Med (Berl)       Date:  2011-05-19       Impact factor: 4.599

4.  Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy.

Authors:  Guangjun Jiao; Tingting Ren; Wei Guo; Chongmin Ren; Kang Yang
Journal:  Tumour Biol       Date:  2015-01-11

5.  Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway.

Authors:  Xiao-Hui Zhang; Ru Feng; Meng Lv; Qian Jiang; Hong-Hu Zhu; Ya-Zhen Qing; Jia-Ling Bao; Xiao-Jun Huang; X Long Zheng
Journal:  Leuk Res       Date:  2013-09-29       Impact factor: 3.156

6.  Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.

Authors:  R Wang; L Xia; J Gabrilove; S Waxman; Y Jing
Journal:  Leukemia       Date:  2012-07-03       Impact factor: 11.528

7.  Inhibition of angiogenesis by arsenic trioxide via TSP-1-TGF-β1-CTGF-VEGF functional module in rheumatoid arthritis.

Authors:  Juan Zhang; Chunling Li; Yining Zheng; Zhiguo Lin; Yue Zhang; Zhiyi Zhang
Journal:  Oncotarget       Date:  2017-08-03

8.  Arsenic trioxide-mediated suppression of miR-182-5p is associated with potent anti-oxidant effects through up-regulation of SESN2.

Authors:  Liang-Ting Lin; Shin-Yi Liu; Jyh-Der Leu; Chun-Yuan Chang; Shih-Hwa Chiou; Te-Chang Lee; Yi-Jang Lee
Journal:  Oncotarget       Date:  2018-03-23

9.  Arsenic Trioxide and Thalidomide Combination Induces Autophagy Along with Apoptosis in Acute Myeloid Cell Lines.

Authors:  Mahnaz Mohammadi Kian; Atousa Haghi; Mahdieh Salami; Bahram Chahardouli; S Hahrbanoo Rostami; Kianoosh Malekzadeh; Hosein Kamranzadeh Foumani; Saeed Mohammadi; Mohsen Nikbakht
Journal:  Cell J       Date:  2019-10-14       Impact factor: 3.128

10.  Exploring the Mechanisms of Arsenic Trioxide (Pishuang) in Hepatocellular Carcinoma Based on Network Pharmacology.

Authors:  Xinmiao Wang; Luchang Cao; Jingyuan Wu; Guanghui Zhu; Xiaoyu Zhu; Xiaoxiao Zhang; Duoduo Han; Ning Shui; Baoyi Ni; Jie Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-29       Impact factor: 2.629
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.